LENZ Therapeutics (LENZ) Return on Capital Employed (2021 - 2026)
LENZ Therapeutics (LENZ) reported Return on Capital Employed of 44.93% for Q1 2026, down 1516.0% year-over-year from 3.17% in Q1 2025, and down 16.89% on a QoQ basis from 38.44% in Q4 2025.
LENZ Therapeutics (LENZ) has 6 years of Return on Capital Employed data on file, last reported at 44.93% in Q1 2026.
- Quarterly Return on Capital Employed fell 1516.0% year-over-year to 44.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 44.93% (down 1516.0% YoY) and the FY2025 annual result came in at 38.07%, up 619.0% from the prior year.
- Return on Capital Employed eased to 44.93% in Q1 2026 per LENZ's latest filing, from 38.44% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.4% in Q1 2022 and bottomed at 60.74% in Q1 2024.
- The 5-year median for Return on Capital Employed is 31.15% (2025), against an average of 34.18%.
- The widest annual swing landed in 2024, when Return on Capital Employed plunged 3014 bps; it then jumped 3097 bps in 2025.
- Tracing LENZ's Return on Capital Employed over 5 years: stood at 33.5% in 2022, then plunged by 44 bps to 48.35% in 2023, then jumped by 42 bps to 28.01% in 2024, then slumped by 37 bps to 38.44% in 2025, then slipped by 17 bps to 44.93% in 2026.
- Per Business Quant, the three latest LENZ Return on Capital Employed figures stand at 44.93% (Q1 2026), 38.44% (Q4 2025), and 34.34% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -44.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.93% |
| Dec 31, 2025 | -38.44% |
| Sep 30, 2025 | -34.34% |
| Jun 30, 2025 | -31.15% |
| Mar 31, 2025 | -29.77% |
| Dec 31, 2024 | -28.01% |
| Sep 30, 2024 | -33.25% |
| Jun 30, 2024 | -37.39% |
| Mar 31, 2024 | -60.74% |
| Dec 31, 2023 | -48.35% |
| Sep 30, 2023 | -28.09% |
| Jun 30, 2023 | -28.12% |
| Mar 31, 2023 | -30.60% |
| Dec 31, 2022 | -33.50% |
| Sep 30, 2022 | -29.57% |
| Jun 30, 2022 | -24.36% |
| Mar 31, 2022 | -20.40% |
| Dec 31, 2021 | -15.23% |
| Sep 30, 2021 | -12.76% |